市場調査レポート

癌のプロテインキナーゼ治療における競合分析

Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others

発行 BioSeeker Group AB 商品コード 239832
出版日 ページ情報 英文 2940 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
癌のプロテインキナーゼ治療における競合分析 Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others
出版日: 2012年05月01日 ページ情報: 英文 2940 Pages
概要

当レポートでは、世界の212社による648種のプロテインキナーゼ阻害剤の開発戦略について調査分析し、183種の特定済み創薬標的、278種の創薬標的戦略を70種の適応症(癌)の中で評価し、概略以下の構成でお届けいたします。

第1章 エグゼクティブサマリー

第2章 Cancer Highlights™について

第3章 調査手法

第4章 目次

第5章 イントロダクション

第6章 最高の治療成績およびROIのための癌分野におけるプロテインキナーゼ阻害剤の治療標的に関する考察

  • 癌分野における既存薬の再評価
  • イントロダクション:癌分野におけるプロテインキナーゼ阻害剤の標的
  • 癌ゲノムプロジェクトと癌分野におけるプロテインキナーゼ阻害剤の標的
  • プロテインキナーゼ治療:標的に関する利用可能な構造データによって刺激される
  • 癌分野におけるプロテインキナーゼ阻害剤の特定された標的の中での標的間の相互作用
  • 創薬標的の競合環境
  • 癌分野におけるプロテインキナーゼ阻害剤の特定された標的のタンパク質発現レベル
  • 癌分野におけるプロテインキナーゼ阻害剤の経路の評価

第7章 新薬と既存薬:癌分野におけるプロテインキナーゼ阻害剤の創薬標的戦略:開発ステージ別

  • 申請・市販:新しい創薬標的戦略と独自の創薬標的戦略
  • 第3相臨床開発:新しい創薬標的戦略と独自の創薬標的戦略
  • 第2相臨床開発:新しい創薬標的戦略と独自の創薬標的戦略
  • 第1相臨床開発:新しい創薬標的戦略と独自の創薬標的戦略
  • 前臨床開発:新しい創薬標的戦略と独自の創薬標的戦略
  • データなし・延期・中止:創薬標的戦略
  • 癌分野におけるプロテインキナーゼ阻害剤の標的戦略開発プロファイル
  • 癌分野におけるプロテインキナーゼ阻害剤の機構的近似による競合

第8章 化合物戦略:プロテインキナーゼ癌治療薬の競合ベンチマーキング

  • 小分子
  • ペプチド・プロテイン薬
  • 抗体
  • 核酸
  • 細胞・遺伝子治療
  • ドラッグデリバリー・ナノテクノロジー
  • 創薬標的の細胞内の特定に基づいた化合物戦略

第9章 癌分野におけるプロテインキナーゼ阻害剤の主な適応症

  • 急性リンパ性白血病
  • 急性骨髄性白血病
  • 副腎癌
  • B細胞リンパ腫
  • 基底細胞癌
  • 胆道癌
  • 膀胱癌
  • 骨癌
  • 脳腫瘍
  • 乳癌
  • 癌(一般)
  • 癌様腫
  • 子宮頸癌
  • 子宮頚部形成異常
  • 慢性リンパ球性白血病
  • 慢性骨髄性白血病
  • 慢性骨髄単球性白血病
  • CNS癌
  • 直腸癌
  • カウデン症候群
  • 子宮体癌
  • 卵管癌
  • 線維肉腫
  • 消化器癌(一般)
  • 胃癌
  • 消化器癌
  • 頭頚部癌
  • 血液癌(一般)
  • ホジキンリンパ腫
  • 子宮肉腫
  • 白血病(一般)
  • 脂肪肉腫
  • 肝臓癌
  • 肺癌(一般)、など

第10章 パイプライン&ポートフォリオプランニング:癌分野のプロテインキナーゼドラッグパイプラインの競合ベンチマーキング

第11章 免責

図表

目次
Product Code: BSG16158

Abstract

Description

This report represents a new and unique way of stratifying and analyzing the global protein kinase drug pipeline in oncology towards personalized medicine. It will excel your competitive awareness and decrease your decision making time in managing protein kinase drug development in cancer. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

A large number of drugs, both on the market and in development have protein kinase modulating properties.This report includes both direct protein kinase targets and indirect protein kinase targets (non-protein kinase targets which nevertheless have protein kinas effects).

This report comprises defined and up to date development strategies for 648 protein kinase drugs in oncology within the portfolio of 212 companies world-wide, from Ceased to Marketed. The report extensively analyses their 183 identified drug targets, organized into 278 drug target strategies, and assesses them in 70 cancer indications. BioSeeker has applied its unique drug assessment methodology to stratify the protein kinase drug pipeline in oncology and discern the level of competition in fine detail.

Major Findings from this report:

  • The identified competitive landscape of protein kinase drugs in cancer is split between the 30% which have unique drug target strategies and the other 70% which have head-to-head target competing drugs in 81 different clusters. The latter has a competing ratio which is more two times higher than the comparable average of the protein kinase drugs in general.
  • Eight out of every ten drug target strategies in Phase III development are new to protein kinase drugs, whereas only less than four out of every ten target strategies in Phase I are new.
  • The greatest number of new target strategies are found in Preclinical (29%) and Phase II (20%) development.
  • Small molecules, Antibodies and Nucleic Acids drugs are the dominating compound strategies of protein kinase cancer drugs, which represent almost 95% of the entire pipeline.
  • Protein based protein kinase cancer drugs has the highest cross-over of drug target strategies with other compound strategies, especially with that of Small Molecules and Antibodies.
  • Protein kinase drugs are experiencing targeting competition in nearly seven out of every ten cancer indications described, and more so in breast-, non-small cell lung- and colorectal cancer.
  • The highest number of described target strategies among protein kinase drugs are found in breast-, colorectal-, non-small cell lung-, ovarian- and prostate cancer
  • Out of the 212 companies, the highest number of described drug target strategies of protein kinase drugs belongs to Pfizer, AstraZeneca, Novartis, Exelixis and Hoffmann-La Roche

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty.

The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

  • Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
  • Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
  • Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
  • Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
  • Supporting development of integrative molecule, pathway and disease area strategies
  • Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any protein kinase drug in cancer to ensure that the optimal market conditions exist by the time the product is commercialized.

Table of Contents

1. Executive Summary

2. About Cancer Highlights™

  • 2.1. Cancer Focus Areas
  • 2.2. Subscribe Today and Start Saving
    • 2.2.1. Type of License
  • 2.3. Additional Information
  • 2.4. BioSeeker Group's Oncology Team

3. Methodology

  • 3.1. Cancer Highlights'™ Five Pillar Drug Assessment

4. Table of Contents

  • 4.1. List of Figures
  • 4.2. List of Tables

5. Introduction

  • 5.1. The Scope of this Report
  • 5.2. Definitions
  • 5.3. Abbreviations

6. Consider the Therapeutic Target Among Protein Kinase Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment

  • 6.1. Drug Repositioning in Oncology
  • 6.2. Introduction to Targets of Protein Kinase Drugs in Oncology
    • 6.2.1. Antigen Binding Targets
    • 6.2.2. ATPase Activity Targets
    • 6.2.3. Carboxy-lyase Activity Targets
    • 6.2.4. Catalytic Activity Targets
    • 6.2.5. Cell Adhesion Molecule Activity Targets
    • 6.2.6. Chaperone Activity Targets
    • 6.2.7. Chemokine Activity Targets
    • 6.2.8. Cysteine-type Peptidase Activity Targets
    • 6.2.9. Cytokine Activity Targets
    • 6.2.10. Cytoskeletal Protein Binding Targets
    • 6.2.11. DNA Binding Targets
    • 6.2.12. DNA Topoisomerase Activity Targets
    • 6.2.13. Extracellular Ligand-gated Ion Channel Activity Targets
    • 6.2.14. G-protein Coupled Receptor Activity Targets
    • 6.2.15. Growth Factor Activity Targets
    • 6.2.16. GTPase Activator Activity Targets
    • 6.2.17. GTPase Activity Targets
    • 6.2.18. Hydrolase Activity Targets
    • 6.2.19. Ion Channel Activity Targets
    • 6.2.20. Kinase Activity Targets
    • 6.2.21. Kinase Binding Targets
    • 6.2.22. Kinase Regulator Activity Targets
    • 6.2.23. Ligase Activity Targets
    • 6.2.24. Lipid Kinase Activity Targets
    • 6.2.25. Lipid Phosphatase Activity Targets
    • 6.2.26. Molecular Function Unknown Targets
    • 6.2.27. Oxidoreductase Activity Targets
    • 6.2.28. Peroxidase Activity Targets
    • 6.2.29. Protease Inhibitor Activity Targets
    • 6.2.30. Protein Binding Targets
    • 6.2.31. Protein Serine/Threonine Kinase Activity Targets
    • 6.2.32. Protein Threonine/Tyrosine Kinase Activity Targets
    • 6.2.33. Protein Tyrosine/Serine/Threonine Phosphatase Activity Targets
    • 6.2.34. Protein-tyrosine Kinase Activity Targets
    • 6.2.35. Receptor Activity Targets
    • 6.2.36. Receptor Binding Targets
    • 6.2.37. Receptor Signaling Complex Scaffold Activity Targets
    • 6.2.38. Receptor Signaling Protein Serine/Threonine Kinase Activity Targets
    • 6.2.39. Structural Constituent of Cytoskeleton Targets
    • 6.2.40. Structural Molecule Activity Targets
    • 6.2.41. Transcription Factor Activity Targets
    • 6.2.42. Transcription Regulator Activity Targets
    • 6.2.43. Translation Regulator Activity Targets
    • 6.2.44. Transmembrane Receptor Activity Targets
    • 6.2.45. Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
    • 6.2.46. Transporter Activity Targets
  • 6.3. The Cancer Genome Project and Targets of Protein Kinase Drugs in Oncology
    • 6.3.1. Targets of Protein Kinase Drugs in Oncology Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer
  • 6.4. Protein Kinase Therapeutics is Stimulated by Available Structure Data on Targets
  • 6.5. Target-Target Interactions among Identified Targets of Protein Kinase Drugs in Oncology
  • 6.6. The Drug-Target Competitive Landscape
  • 6.7. Protein Expression Levels of Identified Targets of Protein Kinase Drugs in Oncology
  • 6.8. Pathway Assessment of Protein Kinase Drugs in Oncology
    • 6.8.1. Tools for Analysis of Cancer Pathways
    • 6.8.2. Pathway Assessment

7. Emerging New Products to Established Ones: Drug Target Strategies of Protein Kinase Drugs in Oncology by their Highest Stage of Development

  • 7.1. Pre-registration to Marketed: New and Unique Drug Target Strategies of Protein Kinase Drugs in Oncology
  • 7.2. Phase III Clinical Development: New and Unique Drug Target Strategies of Protein Kinase Drugs in Oncology
  • 7.3. Phase II Clinical Development: New and Unique Drug Target Strategies of Protein Kinase Drugs in Oncology
  • 7.4. Phase I Clinical Development: New and Unique Drug Target Strategies of Protein Kinase Drugs in Oncology
  • 7.5. Preclinical Development: New and Unique Drug Target Strategies of Protein Kinase Drugs in Oncology
  • 7.6. Drug Target Strategies of No Data, Suspended or Terminated Protein Kinase Drugs in Oncology
  • 7.7. Target Strategy Development Profiles of Protein Kinase Drugs in Oncology
    • 7.7.1. Marketed
    • 7.7.2. Pre-registration
    • 7.7.3. Phase III
    • 7.7.4. Phase II
    • 7.7.5. Phase I
    • 7.7.6. Preclinical
    • 7.7.7. Suspended
    • 7.7.8. Ceased
  • 7.8. The Competition Through Close Mechanistic Approximation of Protein Kinase Drugs in Oncology

8. Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Cancer Drugs by Compound Strategy

  • 8.1. Small Molecules
    • 8.1.1. Background
    • 8.1.2. Target Strategies of Small Molecule Drugs
  • 8.2. Peptide & Protein Drugs
    • 8.2.1. Background
    • 8.2.2. Target Strategies of Peptide and Protein Drugs
  • 8.3. Antibodies
    • 8.3.1. Background
    • 8.3.2. Target Strategies of Antibody Drugs
  • 8.4. Nucleic Acid Therapies
    • 8.4.1. Background
    • 8.4.2. Target Strategies of Nucleic Acid Drugs
  • 8.5. Cell & Gene Therapy
    • 8.5.1. Background
    • 8.5.2. Target Strategies of Cell & Gene Therapy Drugs
  • 8.6. Drug Delivery and Nanotechnology
    • 8.6.1. Background
    • 8.6.2. Target Strategies of Reformulated Drugs
  • 8.7. Compound Strategies based on Sub-Cellular Localization of Drug Targets

9. Selecting Indication for Protein Kinase Drugs in Oncology

  • 9.1. Acute Lymphocytic Leukemia
  • 9.2. Acute Myelogenous Leukemia
  • 9.3. Adrenal Cancer
  • 9.4. B-cell Lymphoma
  • 9.5. Basal Cell Cancer
  • 9.6. Biliary Cancer
  • 9.7. Bladder Cancer
  • 9.8. Bone Cancer
  • 9.9. Brain Cancer
  • 9.10. Breast Cancer
  • 9.11. Cancer (general)
  • 9.12. Carcinoid
  • 9.13. Cervical Cancer
  • 9.14. Cervical Dysplasia
  • 9.15. Chronic Lymphocytic Leukemia
  • 9.16. Chronic Myelogenous Leukemia
  • 9.17. Chronic Myelomonocytic Leukemia
  • 9.18. CNS Cancer
  • 9.19. Colorectal Cancer
  • 9.20. Cowden syndrome
  • 9.21. Endometrial Cancer
  • 9.22. Fallopian Tube Cancer
  • 9.23. Fibro Sarcoma
  • 9.24. Gastrointestinal Cancer (general)
  • 9.25. Gastrointestinal Stomach Cancer
  • 9.26. Gastrointestinal Stromal Cancer
  • 9.27.. Head and Neck Cancer
  • 9.28. Hematological Cancer (general)
  • 9.29. Hodgkin's Lymphoma
  • 9.30. Leiomyo Sarcoma
  • 9.31. Leukemia (general)
  • 9.32. Lipo Sarcoma
  • 9.33. Liver Cancer
  • 9.34. Lung Cancer (general)
  • 9.35. Lymphangioleiomyomatosis
  • 9.36. Lymphoma (general)
  • 9.37. Mast Cell Leukemia
  • 9.38. Mastocytosis
  • 9.39. Melanoma
  • 9.40. Mesothelioma
  • 9.41. Myelodysplastic Syndrome
  • 9.42. Myeloma
  • 9.43. Nasopharyngeal Cancer
  • 9.44. Neuroblastoma
  • 9.45. Neuroendocrine Cancer (general)
  • 9.46. Neuroendocrine Cancer (pancreatic)
  • 9.47. Neurofibromatosis
  • 9.48. Non-Hodgkin's Lymphoma
  • 9.49. Non-Small Cell Lung Cancer
  • 9.50. Oesophageal Cancer
  • 9.51. Oral Cancer
  • 9.52. Osteo Sarcoma
  • 9.53. Ovarian Cancer
  • 9.54. Pancreatic Cancer
  • 9.55. Peritoneal Cancer
  • 9.56. Prostate Cancer
  • 9.57. Renal Cancer
  • 9.58. Rhabdomyo Sarcoma
  • 9.59. Sarcoma (general)
  • 9.60. Small Cell Lung Cancer
  • 9.61. Soft Tissue Sarcoma
  • 9.62. Solid Tumor
  • 9.63. Squamous Cell Cancer
  • 9.64. Synovial Sarcoma
  • 9.65. T-cell Lymphoma
  • 9.66. Testicular Cancer
  • 9.67. Thymoma Cancer
  • 9.68. Thyroid Cancer
  • 9.69. Unspecified Cancer Indication
  • 9.70. Waldenstrom's hypergammaglobulinemia

10 P.ipeline and Portfolio Planning: Competitive Benchmarking of the Protein Kinase Drug Pipeline in Oncology by Investigator

  • 10.1. Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change
  • 10.2. Company Facts and Ranking
  • 10.3. Competitive Fall-Out Assessment
  • 10.4. 4SC
  • 10.5. AB Science
  • 10.6. Abbott
  • 10.7. Abiogen
  • 10.8. Acceleron Pharma
  • 10.9. ACT Biotech
  • 10.10. Advenchen
  • 10.11. AEgera
  • 10.12. AEterna Zentaris
  • 10.13. Aida Pharmaceuticals
  • 10.14. Alethia Biotherapeutics
  • 10.15. Allist Pharmaceuticals
  • 10.16. Allostera
  • 10.17. AlphaVax
  • 10.18. Ambit Biosciences
  • 10.19. Amgen
  • 10.20. Amphora
  • 10.21. Ansaris
  • 10.22. Apogee Biotechnology
  • 10.23. Ariad
  • 10.24. Arno Therapeutics
  • 10.25. ArQule
  • 10.26. Array BioPharma
  • 10.27. Astellas
  • 10.28. Astex Pharmaceuticals
  • 10.29. AstraZeneca
  • 10.30. Avila Therapeutics
  • 10.31. Bavarian Nordic
  • 10.32. Bayer
  • 10.33. Benitec
  • 10.34. Berkeley Lab
  • 10.35. Bio-Path Holdings
  • 10.36. BioAxone
  • 10.37. Bionovo
  • 10.38. Biotecnol
  • 10.39. Biotica Technology
  • 10.40. Boehringer Ingelheim
  • 10.41. Bristol-Myers Squibb
  • 10.42. BTG
  • 10.43. Callisto Pharmaceuticals
  • 10.44. Cambrex
  • 10.45. CanBas
  • 10.46. Cancer Research Technology
  • 10.47. Catalyst Biosciences
  • 10.48. Celgene
  • 10.49. Cell Therapeutics
  • 10.50. CellCeutix
  • 10.51. Celleron
  • 10.52. Cephalon
  • 10.53. CerRx
  • 10.54. Chroma Therapeutics
  • 10.55. Circadian Technologies
  • 10.56. Cleveland BioLabs
  • 10.57. Clinical Data
  • 10.58. CompleGen
  • 10.59. Compugen
  • 10.60. CoNCERT Pharmaceuticals
  • 10.61. Curis
  • 10.62. Cyclacel
  • 10.63. Cylene Pharmaceuticals
  • 10.64. Cytokine PharmaSciences
  • 10.65. Cytopia
  • 10.66. Daiichi Sankyo
  • 10.67. Dainippon Sumitomo Pharma
  • 10.68. Debiopharm
  • 10.69. Deciphera Pharmaceuticals
  • 10.70. DeveloGen
  • 10.71. DiaMedica
  • 10.72. Dyax
  • 10.73. Eisai
  • 10.74 Elara Pharmaceuticals
  • 10.75. Eli Lilly
  • 10.76. Enkam Pharmaceuticals
  • 10.77. EntreMed
  • 10.78. Enzon
  • 10.79. Erimos
  • 10.80. Exelixis
  • 10.81. Galapagos
  • 10.82. Galena Biopharma
  • 10.83. Generex
  • 10.84. Gilead Sciences
  • 10.85. GlaxoSmithKline
  • 10.86. GlycoGenesys
  • 10.87. GPC Biotech
  • 10.88. Hanmi
  • 10.89. Hoffmann-La Roche
  • 10.90. Hutchison China MediTech
  • 10.91. Hypha Discovery
  • 10.92. Idera Pharmaceuticals
  • 10.93. ImClone Systems
  • 10.94. ImmunoFrontier
  • 10.95. Incozen Therapeutics
  • 10.96. Incyte Corporation
  • 10.97. Inhibiton Therapeutics
  • 10.98. Inovio
  • 10.99. Insmed
  • 10.100. Insys Therapeutics
  • 10.101. Intellikine
  • 10.102. Isis Pharmaceuticals
  • 10.103. ISU ABXIS
  • 10.104. Jina Pharmaceuticals
  • 10.105. Johnson & Johnson
  • 10.106. Kadmon
  • 10.107. KAI Pharmaceuticals
  • 10.108. KaloBios
  • 10.109. Kalypsys
  • 10.110. Karus Therapeutics
  • 10.111. Keryx Biopharmaceuticals
  • 10.112. Kiadis
  • 10.113. Kinex
  • 10.114. Kirin Pharma
  • 10.115. KuDOS
  • 10.116. Kyowa Hakko Kirin
  • 10.117. Leo
  • 10.118. Lexicon Pharmaceuticals
  • 10.119. Ligand
  • 10.120. Marina Biotech
  • 10.121. MaxoCore Pharmaceuticals
  • 10.122. Meda
  • 10.123. Medisyn Technologies
  • 10.124. Merck & Co
  • 10.125. Merck KGaA
  • 10.126. Merrimack
  • 10.127. MethylGene
  • 10.128. Micromet
  • 10.129. Mitsubishi Tanabe Pharma
  • 10.130. Molecular LogiX
  • 10.131. Myrexis
  • 10.132. Nano Terra
  • 10.133. Nerviano Medical Sciences
  • 10.134. NexusPharma
  • 10.135. NicOx
  • 10.136. Nidus Laboratories
  • 10.137. NIH
  • 10.138. Nippon Shinyaku
  • 10.139. Non-industrial Sources
  • 10.140. NovaLead
  • 10.141. Novartis
  • 10.142. Novogen
  • 10.143. Oncalis
  • 10.144. Onconova
  • 10.145. OncoTherapy Science
  • 10.146. Oncothyreon
  • 10.147. OSI Pharmaceuticals
  • 10.148. Pathway Therapeutics
  • 10.149. Peregrine Pharmaceuticals
  • 10.150. Pfizer
  • 10.151. Pharmacyclics
  • 10.152. PharmaGap
  • 10.153. PharmaMar
  • 10.154. Pharmexa
  • 10.155. Phoenix Biotechnology
  • 10.156. PHusis Therapeutics
  • 10.157. Pieris
  • 10.158. Piramal
  • 10.159. PIramed
  • 10.160. Portola Pharmaceuticals
  • 10.161. Proacta
  • 10.162. Progenics Pharmaceuticals
  • 10.163. Provid
  • 10.164. QLT
  • 10.165. Quantum Pharmaceuticals
  • 10.166. Ras Therapeutics
  • 10.167. Reata Pharmaceuticals
  • 10.168. Receptor BioLogix
  • 10.169. Rexahn
  • 10.170. Rigel
  • 10.171. Samtheo Biopharma
  • 10.172. Sanofi
  • 10.173. Sareum
  • 10.174. SBI Biotech
  • 10.175. SBIO
  • 10.176. Scancell
  • 10.177. Schering-Plough
  • 10.178. Selvita
  • 10.179. Semafore Pharmaceuticals
  • 10.180. Sentinel Oncology
  • 10.181. SGX Pharmaceuticals
  • 10.182. Silence Therapeutics
  • 10.183. Sunesis
  • 10.184. Supratek Pharma
  • 10.185. Swedish Orphan Biovitrum
  • 10.186. Switch Pharma
  • 10.187. Symphogen
  • 10.188. Takeda
  • 10.189. Tamir Biotechnology
  • 10.190. Targa Therapeutics
  • 10.191. TargeGen
  • 10.192. TauTaTis
  • 10.193. TCD Pharma
  • 10.194. Tekmira Pharmaceuticals
  • 10.195. Telik
  • 10.196. Teva
  • 10.197. Thallion Pharmaceuticals
  • 10.198. Theryte
  • 10.199. Tigris Pharmaceuticals
  • 10.200. ToolGen
  • 10.201. TopoTarget
  • 10.202. Tragara Pharmaceuticals
  • 10.203. TransTech Pharma
  • 10.204. UCB
  • 10.205. VasGene Therapeutics
  • 10.206. Velacor Therapeutics
  • 10.207. Vernalis
  • 10.208. Vertex Pharmaceuticals
  • 10.209. VioQuest
  • 10.210. ViroMed
  • 10.211. Wyeth
  • 10.212. Xcovery
  • 10.213. Xencor
  • 10.214. YM BioSciences
  • 10.215. Zenyaku Kogyo

11. Disclaimer

List of Figures

  • Figure 1: Visualization of Target-Target Interactions among Targets of Protein Kinase Drugs in Oncology
  • Figure 2: The Drug-Target Competitive Landscape of Protein Kinase Drugs in Oncology - Super Cluster
  • Figure 3: The Drug-Target Competitive Landscape Protein Kinase Drugs in Oncology - Smaller Clusters
  • Figure 4: Head-to-Head Targeting Competitive Landscape of Protein Kinase Drugs in Oncology 1 (2)
  • Figure 5: Head-to-Head Targeting Competitive Landscape of Protein Kinase Drugs in Oncology 2 (2)
  • Figure 6: Distribution of Compound Strategies among Protein Kinase Cancer Drugs
  • Figure 7: Primary Sub-cellular Localization of Drug Targets
  • Figure 8: Number of Companies per Ranking Level

List of Tables

  • Table 1: Cancer Highlights'™ Five Pillar Drug Assessment
  • Table 2: Breakdown of the Included Protein Kinase Drug Pipeline in Oncology by Stage of Development
  • Table 3: Head to Head Target Competition among Protein Kinase Drugs in Oncology
  • Table 4: Overview of Drug Target Strategy Themes
  • Table 5: Terminally Ceased Targets of Protein Kinase Drugs in Oncology
  • Table 6: Official Gene Name to Target Profle
  • Table 7: Targets of Protein Kinase Drugs in Oncology Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
  • Table 8: Identity of Drug Targets with Available Biological Structures
  • Table 9: Number of Target-Target Interactions among Targets of Protein Kinase Drugs in Oncology
  • Table 10: Available Protein Expression Profiles of Protein Kinase Drug Targets in Oncology
  • Table 11: Pathway Summary
  • Table 12: Drug Targets without any Identified Assigned Pathways
  • Table 13: Pathway Profiles According to BioCarta of Protein Kinase Drug Targets in Oncology
  • Table 14: Pathway Profiles According to KEGG of Protein Kinase Drug Targets in Oncology
  • Table 15: Pathway Profiles According to NetPath of Protein Kinase Drug Targets in Oncology
  • Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness
  • Table 17: Top Competitive Target Strategies of Protein Kinase Drugs in Oncology
  • Table 18: New and Unique Target Strategies of Pre-registration to Marketed Protein Kinase Drugs in Oncology
  • Table 19: The Competition Through Close Mechanistic Approximation Between Protein Kinase Drugs in Oncology in Pre-registration to Marketed
  • Table 20: New and Unique Target Strategies in Phase III Clinical Development of Protein Kinase Drugs in Oncology
  • Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Protein Kinase Drugs in Oncology
  • Table 22: New and Unique Target Strategies in Phase II Clinical Development of Protein Kinase Drugs in Oncology
  • Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Protein Kinase Drugs in Oncology
  • Table 24: New and Unique Target Strategies in Phase I Clinical Development of Protein Kinase Drugs in Oncology
  • Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Protein Kinase Drugs in Oncology
  • Table 26: New and Unique Target Strategies in Preclinical Development of Protein Kinase Drugs in Oncology
  • Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Protein Kinase Drugs in Oncology
  • Table 28: Target Strategies of No Data, Suspended and Terminated Protein Kinase Drugs in Oncology
  • Table 29: Connecting Target Strategy with Its Profile Identification Number
  • Table 30: The Competition Through Close Mechanistic Approximation Among Protein Kinase Drugs in Oncology
  • Table 31: Overview of Compound Strategy Competition Among Protein Kinase Cancer Drugs
  • Table 32: Overview of the Competitive Landscape of Small Molecule Based Protein Kinase Drugs in Oncology
  • Table 33: Competitive Comparison of Target Strategies of Small Molecule Protein Kinase Cancer Drugs
  • Table 34: Pursued Target Strategies of Small Molecule Drugs Based Protein Kinase Cancer Drugs
  • Table 35: Overview of the Competitive Landscape of Peptide Based Protein Kinase Drugs in Oncology
  • Table 36: Competitive Comparison of Target Strategies of Peptide Based Protein Kinase Cancer Drugs
  • Table 37: Pursued Target Strategies of Peptide Based Protein Kinase Cancer Drugs
  • Table 38: Overview of the Competitive Landscape of Protein Based Protein Kinase Drugs in Oncology
  • Table 39: Competitive Comparison of Target Strategies of Protein Based Protein Kinase Cancer Drugs
  • Table 40: Pursued Target Strategies of Protein Based Protein Kinase Cancer Drugs
  • Table 41: Overview of the Competitive Landscape of Antibody Based Protein Kinase Drugs in Oncology
  • Table 42: Competitive Comparison of Target Strategies of Antibody Based Protein Kinase Cancer Drugs
  • Table 43: Pursued Target Strategies of Antibody Based Protein Kinase Cancer Drugs
  • Table 44: Overview of the Competitive Landscape of Nucleic Acid Based Protein Kinase Drugs in Oncology
  • Table 45: Competitive Comparison of Target Strategies of Nucleic Acid Based Protein Kinase Cancer Drugs
  • Table 46: Pursued Target Strategies of Nucleic Acid Based Protein Kinase Cancer Drugs
  • Table 47: Potential Forms of Cell Therapy
  • Table 48: Vectors in Gene Therapy
  • Table 49: Overview of the Competitive Landscape of Cell Therapy Based Protein Kinase Drugs in Oncology
  • Table 50: Pursued Target Strategies of Cell Therapy Based Pancreatic Cancer Drugs
  • Table 51: Overview of the Competitive Landscape of Gene Therapy Based Protein Kinase Drugs in Oncology
  • Table 52: Competitive Comparison of Target Strategies of Gene Therapy Based Protein Kinase Cancer Drugs
  • Table 53: Pursued Target Strategies of Gene Therapy Based Protein Kinase Cancer Drugs
  • Table 54:Overview of the Competitive Landscape of Reformulated Protein Kinase Drugs on Oncology
  • Table 55: Pursued Target Strategies of Reformulated Protein Kinase Cancer Drugs
  • Table 56: Compound Strategies based on Sub-Cellular Localization of Protein Kinase Cancer Drug Targets
  • Table 57 Competitive Summary by Cancer Indication of Protein Kinase Drugs
  • Table 58: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Acute Lymphocytic Leukemia
  • Table 59: The Competition through Close Mechanistic Approximation between Acute Lymphocytic Leukemia Drugs
  • Table 60: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Acute Myelogenous Leukemia
  • Table 61: The Competition through Close Mechanistic Approximation between Acute Myelogenous Leukemia Drugs
  • Table 62: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Adrenal Cancer
  • Table 63: The Competition through Close Mechanistic Approximation between Adrenal Cancer Drugs
  • Table 64: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of B-cell Lymphoma
  • Table 65: The Competition through Close Mechanistic Approximation between B-cell Lymphoma Drugs
  • Table 66: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Basal Cell Cancer
  • Table 67: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Biliary Cancer
  • Table 68: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Bladder Cancer
  • Table 69: The Competition through Close Mechanistic Approximation between Bladder Cancer Drugs
  • Table 70: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Bone Cancer
  • Table 71: The Competition through Close Mechanistic Approximation between Bone Cancer Drugs
  • Table 72: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Brain Cancer
  • Table 73: The Competition through Close Mechanistic Approximation between Brain Cancer Drugs
  • Table 74: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Breast Cancer
  • Table 75: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs
  • Table 76: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Cancer (general)
  • Table 77: The Competition through Close Mechanistic Approximation between Cancer (general) Drugs
  • Table 78: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Carcinoid
  • Table 79: The Competition through Close Mechanistic Approximation between Carcinoid Drugs
  • Table 80: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Cervical Cancer
  • Table 81: The Competition through Close Mechanistic Approximation between Cervical Cancer Drugs
  • Table 82: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Cervical Dysplasia
  • Table 83: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Chronic Lymphocytic Leukemia
  • Table 84: The Competition through Close Mechanistic Approximation between Chronic Lymphocytic Leukemia Drugs
  • Table 85: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Chronic Myelogenous Leukemia
  • Table 86: The Competition through Close Mechanistic Approximation between Chronic Myelogenous Leukemia Drugs
  • Table 87: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Chronic Myelomonocytic Leukemia
  • Table 88: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of CNS Cancer
  • Table 89: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Colorectal Cancer
  • Table 90: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs
  • Table 91: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Cowden syndrome
  • Table 92: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Endometrial Cancer
  • Table 93: The Competition through Close Mechanistic Approximation between Endometrial Cancer Drugs
  • Table 94: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Fallopian Tube Cancer
  • Table 95: The Competition through Close Mechanistic Approximation between Fallopian Tube Cancer Drugs
  • Table 96: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Fibro Sarcoma
  • Table 97: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Gastrointestinal Cancer (general)
  • Table 98: The Competition through Close Mechanistic Approximation between Gastrointestinal Cancer (general) Drugs
  • Table 99: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Gastrointestinal Stomach Cancer
  • Table 100: The Competition through Close Mechanistic Approximation between Cancer Drugs
  • Table 101: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Gastrointestinal Stromal Cancer
  • Table 102: The Competition through Close Mechanistic Approximation between Gastrointestinal Stromal Cancer Drugs
  • Table 103: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Head and Neck Cancer
  • Table 104: The Competition through Close Mechanistic Approximation between Head and Neck Cancer Drugs
  • Table 105: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Hematological Cancer (general)
  • Table 106: The Competition through Close Mechanistic Approximation between Hematological Cancer (general) Drugs
  • Table 107: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Hodgkin's Lymphoma
  • Table 108: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Leiomyo Sarcoma
  • Table 109: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Leukemia (general)
  • Table 110: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Lipo Sarcoma
  • Table 111: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Liver Cancer
  • Table 112: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs
  • Table 113: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Lung Cancer (general)
  • Table 114: The Competition through Close Mechanistic Approximation between Lung Cancer (general) Drugs
  • Table 115: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Lymphangioleiomyomatosis
  • Table 116: The Competition through Close Mechanistic Approximation between Lymphangioleiomyomatosis Drugs
  • Table 117: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Lymphoma (general)
  • Table 118: The Competition through Close Mechanistic Approximation between Lymphoma (general) Drugs
  • Table 119: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Mast Cell Leukemia
  • Table 120: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Mastocytosis
  • Table 121: The Competition through Close Mechanistic Approximation between Mastocytosis Drugs
  • Table 122: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Melanoma
  • Table 123: The Competition through Close Mechanistic Approximation between Melanoma Drugs
  • Table 124: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Mesothelioma
  • Table 125: The Competition through Close Mechanistic Approximation between Mesothelioma Drugs
  • Table 126: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Myelodysplastic Syndrome
  • Table 127: The Competition through Close Mechanistic Approximation between Myelodysplastic Syndrome Drugs
  • Table 128: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Myeloma
  • Table 129: The Competition through Close Mechanistic Approximation between Myeloma Drugs
  • Table 130: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Nasopharyngeal Cancer
  • Table 131: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Neuroblastoma
  • Table 132: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Neuroendocrine Cancer (general)
  • Table 133: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Neuroendocrine Cancer (pancreatic)
  • Table 134: The Competition through Close Mechanistic Approximation between Neuroendocrine Cancer (pancreatic) Drugs
  • Table 135: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Neurofibromatosis
  • Table 136: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of non-Hodgkin's Lymphoma
  • Table 137: The Competition through Close Mechanistic Approximation between Non-Hodgkin's Lymphoma Drugs
  • Table 138: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Non-Small Cell Lung Cancer
  • Table 139: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drugs
  • Table 140: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Oesophageal Cancer
  • Table 141: The Competition through Close Mechanistic Approximation between Oesophageal Cancer Drugs
  • Table 142: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Oral Cancer
  • Table 143: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Osteo Sarcoma
  • Table 144: The Competition through Close Mechanistic Approximation between Osteo Sarcoma Drugs
  • Table 145: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Ovarian Cancer
  • Table 146: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs
  • Table 147: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Pancreatic Cancer
  • Table 148: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs
  • Table 149: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Peritoneal Cancer
  • Table 150: The Competition through Close Mechanistic Approximation between Peritoneal Cancer Drugs
  • Table 151: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Prostate Cancer
  • Table 152: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs
  • Table 153: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Renal Cancer
  • Table 154: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs
  • Table 155: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Rhabdomyo Sarcoma
  • Table 156: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Sarcoma (general)
  • Table 157: The Competition through Close Mechanistic Approximation between Sarcoma (general) Drugs
  • Table 158: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Small Cell Lung Cancer
  • Table 159: The Competition through Close Mechanistic Approximation between Small Cell Lung Cancer Drugs
  • Table 160: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Soft Tissue Sarcoma
  • Table 161: The Competition through Close Mechanistic Approximation between Soft Tissue Sarcoma Drugs
  • Table 162: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Solid Tumor
  • Table 163: The Competition through Close Mechanistic Approximation between Solid Tumor Drugs
  • Table 164: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Squamous Cell Cancer
  • Table 165: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Synovial Sarcoma
  • Table 166: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of T-cell Lymphoma
  • Table 167: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Testicular Cancer
  • Table 168: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Thymoma Cancer
  • Table 169: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Thyroid Cancer
  • Table 170: The Competition through Close Mechanistic Approximation between Thyroid Cancer Drugs
  • Table 171: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Unspecified Cancer Indication
  • Table 172: The Competition through Close Mechanistic Approximation between Unspecified Cancer Type Drugs
  • Table 173: Target Strategy Development Profiles of Protein Kinase Drugs for the Treatment of Waldenstrom's hypergammaglobulinemia
  • Table 174: Competitive Summary by Investigator of Protein Kinase Drug Development
  • Table 175: Summary Table of Corporate Changes in the Competitive Landscape of Protein Kinase Drug Development in Oncology
  • Table 176: The Worst Ranking and the Highest Populated Level for Each of the 15 Ranking Parameters
  • Table 177: Example of a Competitive Fall-Out Table (Targeting KDR/Modified)
  • Table 178: 4SC's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 179: AB Science's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 180: Abbott's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 181: Abiogen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 182: Acceleron Pharma's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 183: ACT Biotech's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 184: Advenchen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 185: AEgera's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 186: AEterna Zentaris' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 187: Aida Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 188: Alethia Biotherapeutics' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 189: Allist Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 190: Allostera's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 191: AlphaVax's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 192: Ambit Biosciences' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 193: Amgen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 194: Amphora's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 195: Ansaris' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 196: Apogee Biotechnology's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 197: Ariad's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 198: Arno Therapeutics' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 199: ArQule's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 200: Array BioPharma's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 201: Astellas' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 202: Astex Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 203: AstraZeneca's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 204: Avila Therapeutics' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 205: Bavarian Nordic's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 206: Bayer's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 207: Benitec's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 208: Berkeley Lab's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 209: Bio-Path Holdings' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 210: BioAxone's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 211: Bionovo's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 212: Biotecnol's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 213: Biotica Technology's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 214: Boehringer Ingelheim's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 215: Bristol-Myers Squibb's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 216: BTG's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 217: Callisto Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 218: Cambrex's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 219: CanBas' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 220: Cancer Research Technology's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 221: Catalyst Biosciences' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 222: Celgene's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 223: Cell Therapeutics' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 224: CellCeutix's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 225: Celleron's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 226: Cephalon's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 227: CerRx's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 228: Chroma Therapeutics' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 229: Circadian Technologies' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 230: Cleveland BioLabs' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 231: Clinical Data's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 232: CompleGen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 233: Compugen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 234: CoNCERT Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 235: Curis' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 236: Cyclacel's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 237: Cylene Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 238: Cytokine PharmaSciences' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 239: Cytopia's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 240: Daiichi Sankyo's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 241: Dainippon Sumitomo Pharma's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 242: Debiopharm's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 243: Deciphera Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 244: DeveloGen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 245: DiaMedica's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 246: Dyax's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 247: Eisai's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 248: Elara Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 249: Eli Lilly's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 250: Enkam Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 251: EntreMed's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 252: Enzon's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 253: Erimos' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 254: Exelixis' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 255: Galapagos' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 256: Galena Biopharma's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 257: Generex's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 258: Gilead Sciences' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 259: GlaxoSmithKline's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 260: GlycoGenesys' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 261: GPC Biotech's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 262: Hanmi's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 263: Hoffmann-La Roche's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 264: Hutchison China MediTech's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 265: Hypha Discovery's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 266: Idera Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 267: ImClone Systems' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 268: ImmunoFrontier's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 269: Incozen Therapeutics' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 270: Incyte Corporation's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 271: Inhibiton Therapeutics' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 272: Inovio's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 273: Insmed's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 274: Insys Therapeutics' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 275: Intellikine's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 276: Isis Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 277: ISU ABXIS' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 278: Jina Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 279: Johnson & Johnson's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 280: Kadmon's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 281: KAI Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 282: KaloBios' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 283: Kalypsys' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 284: Karus Therapeutics' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 285: Keryx Biopharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 286: Kiadis' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 287: Kinex's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 288: Kirin Pharma's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 289: KuDOS' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 290: Kyowa Hakko Kirin's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 291: Leo's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 292: Lexicon Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 293: Ligand's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 294: Marina Biotech's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 295: MaxoCore Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 296: Meda's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 297: Medisyn Technologies' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 298: Merck & Co's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 299: Merck KGaA's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 300: Merrimack's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 301: MethylGene's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 302: Micromet's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 303: Mitsubishi Tanabe Pharma's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 304: Molecular LogiX's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 305: Myrexis' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 306: Nano Terra's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 307: Nerviano Medical Sciences' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 308: NexusPharma's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 309: NicOx's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 310: Nidus Laboratories' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 311: NIH's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 312: Nippon Shinyaku's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 313: Non-industrial source's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 314: NovaLead's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 315: Novartis' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 316: Novogen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 317: Oncalis' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 318: Onconova's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 319: OncoTherapy Science's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 320: Oncothyreon's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 321: OSI Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 322: Pathway Therapeutics' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 323: Peregrine Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 324: Pfizer's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 325: Pharmacyclics' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 326: PharmaGap's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 327: PharmaMar's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 328: Pharmexa's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 329: Phoenix Biotechnology's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 330: PHusis Therapeutics' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 331: Pieris' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 332: Piramal's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 333: PIramed's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 334: Portola Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 335: Proacta's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 336: Progenics Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 337: Provid's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 338: QLT's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 339: Quantum Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 340: Ras Therapeutics' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 341: Reata Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 342: Receptor BioLogix's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 343: Rexahn's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 344: Rigel's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 345: Samtheo Biopharma's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 346: Sanofi's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 347: Sareum's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 348: SBI Biotech's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 349: SBIO's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 350: Scancell's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 351: Schering-Plough's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 352: Selvita's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 353: Semafore Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 354: Sentinel Oncology's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 355: SGX Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 356: Silence Therapeutics' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 357: Sunesis' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 358: Supratek Pharma's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 359: Swedish Orphan Biovitrum's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 360: Switch Pharma's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 361: Symphogen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 362: Takeda's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 363: Tamir Biotechnology's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 364: Targa Therapeutics' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 365: TargeGen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 366: TauTaTis' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 367: TCD Pharma's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 368: Tekmira Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 369: Telik's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 370: Teva's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 371: Thallion Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 372: Theryte's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 373: Tigris Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 374: ToolGen's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 375: TopoTarget's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 376: Tragara Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 377: TransTech Pharma's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 378: UCB's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 379: VasGene Therapeutics' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 380: Velacor Therapeutics' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 381: Vernalis' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 382: Vertex Pharmaceuticals' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 383: VioQuest's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 384: ViroMed's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 385: Wyeth's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 386: Xcovery's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 387: Xencor's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 388: YM BioSciences' Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
  • Table 389: Zenyaku Kogyo's Included Protein Kinase Drugs in Oncology and Competitive Fall-Out
Back to Top